Buy Evolent Health

Logo for stock EVH (Evolent Health)

Amount

£
GBP

Latest price

$5.16
(£1.00 = $1.316)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$553.50M

P/E ratio

-3.15

EPS

-$1.572

Beta

0.30

Dividend rate

N/A

Dividend yield

N/A

About

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers three primary solutions: specialty care management services, total cost of care management and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its total cost of care management solution enables providers to manage populations they may be accountable for under value-based contracts with payers or accountable care organizations (ACO) contracts with Centers for Medicare and Medicaid Services (CMS). Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

CEO

Mr. Seth Blackley

Employees

4,500

Sector

Services

Company HQ

ARLINGTON, United States of America

News

Logo for news article #0 (Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript)

Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript

Evolent Health, Inc. ( EVH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Seth Blackley - Co-Founder, CEO & Director John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Daniel Grosslight - Citigroup Inc., Research Division John Stansel - JPMorgan Chase & Co, Research Division Lucas Romanski - TD Cowen, Research Division Eduardo Ron - Truist Securities, Inc., Research Division Jeffrey Garro - Stephens Inc., Research Division Jessica Tassan - Piper Sandler & Co., Research Division David Larsen - BTIG, LLC, Research Division Matthew Shea - Needham & Company, LLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Presentation Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter ended September 30, 2025. As a reminder, this conference call is being recorded.

Seeking Alpha

November 07, 2025

Logo for news article #1 (Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics)

Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics

The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research

November 07, 2025

Logo for news article #2 (Evolent Health (EVH) Misses Q3 Earnings Estimates)

Evolent Health (EVH) Misses Q3 Earnings Estimates

Evolent Health (EVH) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.04 per share a year ago.

Zacks Investment Research

November 07, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.